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Genetics and Genomics
Detection of circulating tumour DNA is associated with
inferior outcomes in Ewing sarcoma and osteosarcoma: a
report from the Children’s Oncology Group
David S. Shulman1, Kelly Klega1, Alma Imamovic-Tuco1, Andrea Clapp2, Anwesha Nag2, Aaron R. Thorner2, Eliezer Van Allen3,4,
Gavin Ha4, Stephen L. Lessnick5, Richard Gorlick6, Katherine A. Janeway1, Patrick J. Leavey7, Leo Mascarenhas8, Wendy B. London1,
Kieuhoa T. Vo9, Kimberly Stegmaier1, David Hall10, Mark D. Krailo10,11, Donald A. Barkauskas10,11, Steven G. DuBois1 and
Brian D. Crompton1,4,12
BACKGROUND: New prognostic markers are needed to identify patients with Ewing sarcoma (EWS) and osteosarcoma unlikely to
benefit from standard therapy. We describe the incidence and association with outcome of circulating tumour DNA (ctDNA) using
next-generation sequencing (NGS) assays.
METHODS: A NGS hybrid capture assay and an ultra-low-pass whole-genome sequencing assay were used to detect ctDNA in
banked plasma from patients with EWS and osteosarcoma, respectively. Patients were coded as positive or negative for ctDNA and
tested for association with clinical features and outcome.
RESULTS: The analytic cohort included 94 patients with EWS (82% from initial diagnosis) and 72 patients with primary localised
osteosarcoma (100% from initial diagnosis). ctDNA was detectable in 53% and 57% of newly diagnosed patients with EWS and
osteosarcoma, respectively. Among patients with newly diagnosed localised EWS, detectable ctDNA was associated with inferior 3-
year event-free survival (48.6% vs. 82.1%; p= 0.006) and overall survival (79.8% vs. 92.6%; p= 0.01). In both EWS and osteosarcoma,
risk of event and death increased with ctDNA levels.
CONCLUSIONS: NGS assays agnostic of primary tumour sequencing results detect ctDNA in half of the plasma samples from
patients with newly diagnosed EWS and osteosarcoma. Detectable ctDNA is associated with inferior outcomes.
British Journal of Cancer (2018) 119:615–621; https://doi.org/10.1038/s41416-018-0212-9
INTRODUCTION
Ewing sarcoma and osteosarcoma are the most common bone
malignancies of childhood and adolescence. Approximately
70–75% of patients with either localised Ewing sarcoma or
osteosarcoma are expected to survive their disease with
multiagent chemotherapy regimens and local control of the
primary tumour.1–4 While a range of clinical prognostic factors
(e.g., tumour site and response to therapy) have been evaluated in
these diseases,5–7 identification of the 25–30% of patients with
localised disease with inadequate outcomes remains challenging.
Development of circulating prognostic biomarkers in patients
with localised disease is a high priority. Ewing sarcoma is
characterised by hallmark translocation events (most commonly
EWSR1/FLI1). Prior studies have evaluated the prognostic impact of
fusion transcript detection in the peripheral blood or bone
marrow using reverse transcription-polymerase chain reaction, yet
have not shown consistent prognostic value.8,9 Likewise, measures
of Ewing sarcoma tumour cells in the peripheral blood and bone
marrow by flow cytometry were not prognostic.9–11 A range of
circulating biomarkers have been evaluated in osteosarcoma,
though none yet validated.12–15
Circulating tumour DNA (ctDNA)-based assays hold promise as
potentially important peripheral biomarkers. Successful utilisation
of ctDNA for disease prognostication and association with
response to therapy in patients with carcinomas has relied on
the identification of highly recurrent single-nucleotide variants
(SNVs).16 Pediatric solid tumours are less amenable to such
approaches, because these malignancies lack recurrent SNVs.
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Ewing sarcoma and osteosarcoma are at opposite ends of
the spectrum of cancer genomic complexity. Ewing sarcoma is
characterised by a simple translocation-driven genome,
with STAG2 and TP53 loss-of-function mutations found in a
minority of tumours.17–19 The majority of Ewing sarcoma
tumours express an EWSR1/ETS translocation with a patient-
specific intronic breakpoint, precluding the use of an assay that
detects a single breakpoint across patients. Prior groups have
detected ctDNA in patients with Ewing sarcoma using patient-
specific digital droplet PCR (ddPCR) or hybrid capture next-
generation sequencing (NGS).20–22 In this study, we utilised a
custom hybrid capture NGS assay, termed TranSS-Seq, which we
previously validated to detect ctDNA from patients with Ewing
sarcoma.23
The osteosarcoma genome is characterised by complex
translocations and copy number changes. 8q gains are relatively
common, may reflect MYC copy number gain/amplification, and
may confer an inferior prognosis.24 Prior attempts to identify
ctDNA in the peripheral blood of patients with osteosarcoma
utilised tumour biopsy sequencing to create probes for ctDNA
detection and targeted NGS of commonly mutated genes.25,26
Ultra-low-pass whole-genome sequencing (ULP-WGS) is a NGS
method capable of identifying the complex structural variants
seen in osteosarcoma.27 These divergent patterns of genomic
aberration (translocation associated vs. complex structural
changes) are common in pediatric malignancies and provide
potential avenues for detection of ctDNA.
In this context, we conducted a retrospective cohort study
to evaluate two NGS ctDNA methods capable of ctDNA
detection without available tumour sequencing in patients with
these diseases. We hypothesised that ctDNA would be
detectable in blood samples and that the presence and level
of ctDNA would be associated with clinical outcomes in patients
with newly diagnosed localised disease. When possible, we
controlled for previously described clinical features associated
with outcomes in these diseases. Finally, we leveraged these
techniques to study additional tumour characteristics (STAG2
and TP53 mutations in Ewing sarcoma; 8q gain in osteosarcoma)
in ctDNA.
METHODS
Patient eligibility and sample collection
Ewing sarcoma cohort. Patients in the Ewing sarcoma cohort
were required to have a pathologic diagnosis of Ewing sarcoma
and be enrolled on the COG Ewing sarcoma biology study
AEWS07B1. Patients included in the primary analysis were
required to have newly diagnosed localised disease. Samples
from patients who presented with newly diagnosed metastatic
disease or recurrent disease were analysed as separate cohorts.
For each patient, ctDNA was analysed from a single blood
sample drawn within 28 days of diagnosis or relapse and prior to
the start of therapy. Each participating centre obtained a blood
sample in an EDTA tube that was shipped overnight at room
temperature to the University of California, San Francisco. On
arrival, all samples were centrifuged, plasma was isolated, and
then frozen at −70 °C until ctDNA analysis. The median plasma
volume for this cohort was 2 mL (range, 0.75–2.0).
Osteosarcoma cohort. Patients in the osteosarcoma cohort were
required to have a new pathologic diagnosis of localised
osteosarcoma and were enrolled on the COG osteosarcoma
biology study AOST06B1. Each patient had a blood sample
collected in an EDTA tube prior to the start of therapy. Plasma was
isolated on-site and frozen at −70 °C before being shipped to
Nationwide Children’s for storage prior to ctDNA analysis.
The median plasma volume for this cohort was 2 mL
(range, 0.75–6.75).
Both cohorts. All patients signed written informed consent at the
time of enrollment to AEWS07B1 or AOST06B1. Separate approval
for this retrospective use of patient samples and clinical data was
obtained from the Dana-Farber/Harvard Cancer Center institu-
tional review board.
ctDNA analysis
Cell-free DNA was extracted from plasma samples using the
QIAamp Circulating Nucleic Acid Kit (Qiagen). Quantification of
total cell-free DNA in ng/mL was performed using Quant-iT
PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific). Contamina-
tion of the sample with high-molecular weight DNA was
determined by Bioanalyzer (Agilent) and an SPRI clean-up was
performed to select for ctDNA if necessary. In total, 37 (39%)
samples from patients with Ewing sarcoma and 2 (3%) patients
with osteosarcoma underwent SPRI clean-up. Up to 40 ng of DNA
were used for library preparation using the KAPA Hyper Prep Kit
(Kapa Biosystems). Barcoded adapters were ligated during manual
library preparation. Libraries were assessed by Bioanalyzer and
quantified for pooling using the MiSeq Nano flow cell.
For detection of Ewing translocations, sequencing libraries were
enriched using the Agilent SureSelectXT Hybrid Capture Kit and a
validated custom bait set targeting intronic regions of genes
commonly involved in sarcoma translocations, including EWSR1,
FUS, CIC, and CCNB3 and the coding regions of TP53 and STAG2.
This approach, termed TranSS-Seq, allows for the detection of
translocations involving these genes and any translocation partner
as well as coding mutations in TP53 and STAG2. Post-enrichment
libraries were quantified and sequenced with intended unique
coverage at target regions of >500×. The average measured
coverage at enrichment sites for all samples tested by this
approach was 579× (range 151.8–1311.2×).
For ULP-WGS for osteosarcoma samples, barcoded sequencing
libraries were pooled and sequenced on an Illumina HiSeq 2500 to
achieve an anticipated average coverage between 0.2× and 1× for
the whole human genome.
Samples for both TranSS-Seq and ULP-WGS were de-multi-
plexed, aligned, and processed using Picard tools, BWA alignment
tool, and GATK tool.28–30 Identification of targeted translocations
by TranSS-Seq was performed using BreaKmer.31 To quantify the
number of translocation reads and wild-type reads for every
sample, each sequencing read was realigned to either the human
reference genome or a custom sequence containing the patient-
specific EWSR1/ETS translocation based on sequence homology.
Percent ctDNA was calculated based on the expectation that each
cancer genome contains one translocated and one wild-type
EWSR1 allele, while normal genomes contain two wild-type EWSR1
alleles: % ctDNA= T/(((W− T)/2)+ T), where T is the number of
translocation reads and W is the number of wild-type reads. In a
previous study, we demonstrated that ctDNA levels determined
with TranSS-Seq were highly correlated with experimental serial
dilution experiments and levels measured by patient-specific
ddPCR. We also demonstrated that TranSS-Seq has an estimated
sensitivity for detection of Ewing sarcoma ctDNA levels at or
below 1.5% of total cell-free DNA.23
ULP-WGS analysis was performed using the Broad Institute’s
ichorCNA algorithm, with manual curation of results to confirm
tumour percentages.27 Previous studies demonstrate that ULP-
WGS can be used to identify ctDNA in patients with copy number-
altered tumours. Serial dilution experiments validated that this
approach can detect and accurately quantify ctDNA when
constituting as little as 3% of a cell-free DNA sample.23
Independent variables
The primary independent variable was ctDNA coded as positive or
negative ('ctDNA positivity') for detectable fusion ctDNA in the
Ewing sarcoma cohort or detectable copy number alterations in
the osteosarcoma cohort. Percent ctDNA and total cell-free DNA
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(ng/mL) were analysed as separate continuous variables and
provided a secondary independent variables for analysis.
Dependent variables
The following variables obtained from AEWS07B1 and AOST06B1
were used to characterise patients: age at study enrollment; sex;
whether the sample was drawn at the time of initial diagnosis or
at relapse (relevant for Ewing sarcoma cohort only); stage; primary
site; and vital status. Age was dichotomised for multivariate
analysis to <18 or ≥18 for patients with Ewing sarcoma and <14 or
≥14 for patients with osteosarcoma.6,32 Tumour size was
measured as largest diameter in a subset of patients with Ewing
sarcoma treated on a COG clinical trial (NCT01231906) and
dichotomised according to established prognostic size criteria of
<8 cm or ≥8 cm.1 The primary endpoint was event-free survival
(EFS) and was defined as time from enrollment to first episode of
disease progression, second malignancy, or death, with patients
without event censored at last follow-up. Overall survival (OS) was
defined as time from enrollment to death, with alive patients
censored at last follow-up
Statistical analysis
This binary predictor variable 'ctDNA positivity' was tested for
association with clinical and demographic features using Fisher's
exact tests and t tests as appropriate. Cell-free DNA quantities
were tested for association with clinical features using Wilcoxon's
rank-sum tests. Cell-free DNA was analysed as a continuous
variable and tested for correlation with percent ctDNA using the
Spearman's correlation coefficient. EFS and OS were estimated by
Kaplan–Meier methods with 95% confidence intervals (CIs).
Potential associations between EFS or OS with ctDNA positivity
were tested with log-rank tests. We used Cox proportional hazards
models of EFS and OS to assess the prognostic impact of the
continuous ctDNA and cell-free DNA secondary predictors and to
assess prognostic impact of ctDNA positivity independent of other
prognostic factors in these diseases. A global test of proportional
hazards was used to confirm the proportional hazards assumption.
All p values are two-sided and a p value < 0.05 was considered
statistically significant. All statistical analyses were performed with
Stata®.
RESULTS
Patient characteristics
We analysed ctDNA in 100 blood samples from 98 unique patients
with Ewing sarcoma. Samples not drawn at the time of diagnosis
or relapse (n= 4) and subsequent samples drawn from the same
patient with a sample from an earlier timepoint (n= 2) were
excluded. The Ewing sarcoma analytical cohort therefore included
94 patients (Table 1).
We analysed ctDNA in 75 blood samples from 75 unique
patients with newly diagnosed, localised osteosarcoma, each with
a single blood sample taken at the time of diagnosis. Three
patients presented with osteosarcoma as a secondary malignancy
and were excluded a priori. The osteosarcoma analytical cohort
therefore included 72 patients with primary osteosarcoma
(Table 1).
ctDNA is detectable at the time of diagnosis and relapse in
patients with bone malignancies
Within the Ewing sarcoma cohort, we detected ctDNA in 53.3%
(41/77) of newly diagnosed patients and 47.1% (8/17) of patients
with relapsed disease (p= 0.79; Table 2). Among patients with
newly diagnosed Ewing sarcoma with detectable ctDNA, the
median percent of total cell-free DNA that was ctDNA containing
an EWSR1 translocation was 13.8% (range 1.4–43.2%). The median
quantity of total cell-free DNA was 14.2 ng/mL (range 2.4–255.3).
Table 1. Characteristics of 94 patients with Ewing sarcoma and 72
patients with osteosarcoma with available ctDNA results
Ewing sarcoma
cohort (n = 94)
Osteosarcoma cohort
(n = 72)
Sex
Male 53 (56.4) 46 (63.9)
Female 41 (43.6) 26 (36.1)
Age at diagnosis, years
(median, range)
14.1 (1.9–20.6)a 13.6 (5.6–22.4)
Primary disease site
Pelvic 20 (26.3)b
Non-pelvic 56 (73.7)
Femur 31 (43.1)
Tibia 24 (33.3)
Humerus 8 (11.1)
Fibula 5 (6.9)
Other 4 (5.6)
Stage at diagnosis
Localised 52 (63.4)c 72 (100)
Metastatic 30 (36.6) 0 (0)
Time of sample acquisition
Initial diagnosis 77 (81.9) 72 (100)
Relapse 17 (18.1) 0 (0)
aAge at diagnosis available for 77 patients with newly diagnosed disease.
bPrimary site data available for 76 patients with Ewing sarcoma. cStage at
diagnosis available for 82 patients with Ewing sarcoma
Table 2. Association between ctDNA detection and clinical features in
patients with Ewing sarcoma and osteosarcoma
ctDNA positive ctDNA negative p value
Ewing sarcoma (n = 94)
Full cohort 49 (52.1) 45 (47.9)
Initial diagnosis (n= 77) 41 (53.3)a 36 (46.8) 0.79
Relapse (N= 17) 8 (47.1) 9 (52.9)
Initial diagnosis (n= 77)
Age (mean, 95% CI) 13.4 (12.1–14.8) 13.3 (11.8–14.8) 0.85
Male 23 (54.8) 19 (45.2) 0.82
Female 18 (51.4) 17 (48.6)
Metastatic 18 (69.2) 8 (30.8) 0.053
Non-metastatic 22 (44.0) 28 (56.0)
Pelvic primary 12 (66.7) 6 (33.3) 0.18
Non-pelvic primary 25 (46.3) 29 (53.7)
Tumour size <8 cm 5 (33.3) 10 (66.7) 0.063
Tumour size ≥8 cm 5 (83.3) 1 (16.7)
Osteosarcoma (n= 72)
Full cohort 41 (56.9) 31 (43.1)
Age (mean, 95% CI) 14.0 (12.9–15.2) 12.9 (11.4–14.3) 0.2
Male 25 (54.4)a 21 (45.7) 0.63
Female 16 (61.5) 10 (38.5)
Femur primary 22 (71.0) 9 (29.0) 0.054
Other primary 19 (46.3) 22 (53.7)
aPercentages do not equal 100% due to rounding
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There was a weak correlation between total cell-free DNA and
percent ctDNA (Supplemental Fig. 1).
The 49 positive samples included EWSR1/FLI1 (n= 43), EWSR1/
ERG (n= 5), and one novel EWSR1/CSMD2 fusion. This novel fusion
has not previously been described and we therefore obtained
tumour material and confirmed the presence of this fusion using
PCR (Supplemental Methods and Supplemental Fig. 2).
Within the osteosarcoma cohort, 56.9% (41/72) had detectable
ctDNA. Among patients with osteosarcoma with detectable
ctDNA, the median percent of total cell-free DNA that was ctDNA
was 11% (range 4.6–58%). The median quantity of total cell-free
DNA was 4.5 ng/mL (range 1.7–318.2). There was a weak
correlation between total cell-free DNA and percent ctDNA
(Supplemental Fig. 3).
Detection of ctDNA is associated with clinical features in Ewing
sarcoma and osteosarcoma
We compared binary detection of ctDNA with presenting patient
and tumour characteristics (Table 2). Among patients with newly
diagnosed Ewing sarcoma, ctDNA was detected in 69.2% of
patients with metastatic disease compared to 44.0% of patients
with localised disease (p= 0.053). ctDNA was detected in 66.7% of
patients with newly diagnosed pelvic Ewing sarcoma compared to
46.3% of patients with non-pelvic Ewing sarcoma (p= 0.18).
Among patients with tumour size collected (n= 21), 83.3% of
patients with tumour size ≥8 cm maximum diameter had
detectable ctDNA compared to 33.3% of patients with tumour
size <8 cm maximum diameter (p= 0.063, Table 2). In the
osteosarcoma cohort, 71.0% of patients with femoral primary
tumours had detectable ctDNA compared to 46.3% of patients
with tumours originating from other sites (p= 0.054). Total cell-
free DNA was higher among patients with newly diagnosed pelvic
Ewing sarcoma compared to non-pelvic sites, but no other
significant associations were seen between total cell-free DNA and
clinical features in either Ewing sarcoma or osteosarcoma
(Supplemental Tables 1 and 2).
Presence of detectable ctDNA is associated with inferior outcomes
in Ewing sarcoma
Clinical outcome data and ctDNA results were available for 50
patients with newly diagnosed localised Ewing sarcoma (median
follow-up 41 months). Patients with detectable ctDNA had inferior
EFS and OS (Fig. 1). The 3-year EFS and OS estimates in patients
with detectable ctDNA were 48.6% (95% CI, 24.2–69.4) and 79.8%
(95% CI, 49.4–93.0) compared to 82.1% (95% CI, 62.3–92.2) and
92.6% (95% CI, 73.4–98.1) in those without detectable ctDNA
(p= 0.006 and 0.0125), respectively. In multivariate analyses,
ctDNA positivity remained prognostic of EFS and OS after
controlling for age and pelvic site (Table 3).
We analysed percent ctDNA as a continuous variable among
patients with newly diagnosed localised Ewing sarcoma. The EFS
and OS hazard ratios (HRs) for each unit increase in percent ctDNA
were 1.06 (95% CI, 1.02–1.09; p= 0.002) and 1.06 (95% CI,
1.02–1.11; p= 0.003), respectively. When limiting the analysis only
to those patients with detectable ctDNA (n= 22), the analogous
HRs were 1.04 (95% CI, 0.99–1.09; p= 0.085) and 1.05 (95% CI,
0.99–1.11; p= 0.12). Among patients with localised Ewing
sarcoma, higher cell-free DNA levels were only associated with
an inferior OS (HR 1.04, 95% CI, 1.01–1.08; p= 0.01; Supplemental
Table 1).
Clinical outcome data and ctDNA results were available for 23
patients with newly diagnosed metastatic Ewing sarcoma. Patients
in this group with detectable ctDNA had inferior EFS compared to
patients with no detectable ctDNA (3-year EFS: 34.1% (95% CI,
12.6–57.2; n= 8) vs. 85.7% (95% CI, 33.4–97.9; n= 18); p= 0.05;
Supplemental Figure 4A). The observed difference in OS according
to ctDNA positivity in this cohort was not statistically significant
(p= 0.24, Supplemental Figure 4B).
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Table 3. Association between ctDNA detection and outcomes in
patients with newly diagnosed localised Ewing sarcoma and
osteosarcoma
HR if ctDNA detected 95% CI p value
Ewing sarcoma (n= 50)
Unadjusted EFS 3.74 1.4–10.1 0.009
Adjusted EFSa 3.85 1.4–10.9 0.011
Unadjusted OS 4.02 1.2–13.1 0.021
Adjusted OSa 3.76 1.06–13.3 0.04
Osteosarcoma (n= 72)
Unadjusted EFS 1.95 0.7–5.08 0.17
Adjusted EFSb 2.26 0.9–5.9 0.098
Unadjusted OS 3.96 0.9–18.1 0.076
Adjusted OSb 4.15 0.9–19.0 0.066
aAdjusted for age <18 vs. age ≥18 years and pelvic primary site. Disease
site available for 49 patients. bAdjusted for age <14 vs. age ≥14 years and
sex
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ctDNA level is associated with inferior outcomes in osteosarcoma
Clinical outcome data and ctDNA results were available for 72
patients with newly diagnosed localised osteosarcoma (median
follow-up 44.3 months). EFS and OS estimates were numerically
lower for patients with detectable ctDNA, but these differences
were not statistically significant (Fig. 2). After controlling for age
(≥14 or <14 years) and sex, two variably reported prognostic
factors in osteosarcoma,6,7 ctDNA detection remained positively
associated with inferior EFS and OS, but the results were also not
statistically significant (Table 3).
Evaluating percent ctDNA as a continuous variable, the HRs for
each unit increase in percent ctDNA among patients with localised
osteosarcoma (n= 72) were 1.06 (95% CI, 1.03–1.09; p < 0.001) and
1.09 (95% CI, 1.06–1.14; p < 0.001) for EFS and OS, respectively.
When limiting the analysis to the 41 patients with detectable
ctDNA, the analogous HRs were 1.07 (95% CI, 1.036–1.11; p <
0.001) and 1.10 (95% CI, 1.05–1.16; p < 0.001). Among all patients
with newly diagnosed osteosarcoma, cell-free DNA levels were not
associated with clinical outcomes (Supplemental Table 2).
Identification of genetic features of Ewing sarcoma and
osteosarcoma via ctDNA
We attempted to determine whether potentially prognostic
genetic features could be detected in ctDNA in patients with
Ewing sarcoma and osteosarcoma. We were able to detect loss-of-
function STAG2 mutations in three patients and TP53 mutations in
four patients. The allelic fraction of these mutations correlated
with the % ctDNA levels observed in the patient sample
suggesting these are likely somatic events. Furthermore, as
germline STAG2 loss-of-function mutations have not been
described, these mutations are expected to be somatic. Although
germline TP53 mutations in Ewing sarcoma are rare,33 we cannot
definitively confirm that these events were somatic in the absence
of germline DNA.
In osteosarcoma, we focused on 8q gain as a specific biological
feature of interest. Among the 41 patients with detectable ctDNA
in the osteosarcoma cohort, 8q gain was detected in 74.4% (32/
43). The 3-year EFS for patients with 8q gain (n= 32) in ctDNA was
60.0% (95% CI, 40.5–75.0) compared to 80.9 (95% CI, 42.4–94.9) in
patients without 8q gain (n= 11) in ctDNA (p= 0.18; Fig. 3).
DISCUSSION
Using two NGS ctDNA assays, we detected ctDNA in banked
peripheral blood samples from 52.1% of patients with Ewing
sarcoma and 56.9% of patients with osteosarcoma, all without the
knowledge of tumour tissue sequencing results. Detectable ctDNA
showed trends toward significant associations with metastatic
disease and tumour size in Ewing sarcoma and with femoral
primary site in osteosarcoma. Among patients with newly
diagnosed localised Ewing sarcoma, binary detection of ctDNA
was associated with an inferior outcome. In both diseases, an
increased risk of event and death was significantly associated with
an increase in ctDNA burden when evaluated as a continuous
variable, a finding that was not seen when using total cell-free
DNA as the marker of interest. Our study is therefore the first large
study to demonstrate that qualitative and quantitative ctDNA
detection provides prognostic information for patients with
localised bone tumours. Finally, we identified additional genomic
features from ctDNA including identification of a previously
undescribed EWSR1 fusion, STAG2 loss in Ewing sarcoma, and 8q
gain in osteosarcoma. Our results demonstrate that these two
ctDNA assays may yield additional information about tumour
biology.
While ctDNA analysis has proven useful for patients with
carcinomas, there have been relatively few studies evaluating the
utility of ctDNA as a biomarker in patients with sarcomas. Four
studies have demonstrated that detection of ctDNA using ddPCR
or hybrid capture-based NGS is feasible in Ewing sarcoma but
each effort had too few patients to demonstrate a prognostic
value of these assays.20–23 A similar approach has been utilised in
a small cohort of patients with chondrosarcoma,34 and two studies
including patients with osteosarcoma.25,26 Our study demon-
strates the feasibility of detecting ctDNA naïve of the tumour
genome. Leveraging thematic genome alterations in these two
genomically diverse tumours provided an avenue to efficiently
detect ctDNA in diseases without highly recurrent SNVs. The fact
that these two approaches do not rely upon first sequencing a
patient’s tumour has advantages for evaluation of ctDNA in large
retrospective cohorts, and in multicentre studies where tumour
biopsy tissue might not be readily available. Further, such
approaches may be generalisable to other tumours that are
translocation-driven or characterised by copy number variations.
For patients with these diseases, risk stratification has histori-
cally depended on the presence of radiologically detected
metastatic disease, and in some instances, primary disease site.
Currently, there is no validated tool available at initial diagnosis to
identify patients with localised disease at high risk of relapse.
While the detection of specific highly recurrent SNVs using ctDNA
in pre-treated, colorectal carcinomas has been associated with
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prognosis,35 prior attempts to utilise pre-treatment circulating
tumour markers of poor prognosis in Ewing sarcoma have failed to
show a consistent association with outcome.8,9 The most
successful prior attempts to identify circulating prognostic
biomarkers in osteosarcoma have utilised microRNA.14,15 We
demonstrate the potential for ctDNA burden at initial diagnosis
to be utilised as a prognostic biomarker of inferior outcomes in
these two diseases. Given that in other diseases ctDNA has been
associated with stage or disease burden,36,37 it is possible that
ctDNA levels may be associated with disease burden or occult
metastatic disease in the context of these sarcomas. If validated,
these assays may improve risk stratification through identification
of patients with localised disease at high risk of relapse.
All samples analysed in our study were collected as part of COG
biology studies and banked. The samples were collected on these
studies without a specific plan for future ctDNA evaluation.
Therefore, the collection and handling strategies used in these
studies were not ideal for maintaining the integrity of ctDNA
samples. That ctDNA was detectable in nearly half of all samples
speaks to the robust nature of these assays. Although it will be
important to validate these findings in a prospective study, the
use of previously banked samples provided the only opportunity
to perform a timely evaluation of the prognostic value of ctDNA in
these two rare diseases. Furthermore, this study now justified the
development of a recently opened prospective study which will
optimise sample collection and allow for prospective validation of
our findings. Similarly, tumour size, a key clinical feature needed to
assess tumour burden, was available only for a subset of patients
and was assessed in a non-uniform fashion, potentially limiting
the possibility for detecting a strong association with ctDNA
positivity. Another limitation of our ctDNA assays is that they were
not optimised to identify point mutations in samples with low
cancer genome fraction, a problem which may have been
compounded by sample quality in the context of this retro-
spective study. Yet, we could detect mutations in TP53 and STAG2
in a limited set of ctDNA Ewing sarcoma samples. We caution that
these mutations, particularly mutations in TP53, may in fact be
heterozygous germline mutations. Such analysis would be more
robust with available germline sequencing and serial ctDNA
samples, which were not available for these two cohorts of
patients.
In summary, the use of two NGS ctDNA assays provides a robust
means of detecting ctDNA in the absence of tumour biopsy tissue
for two rare and genomically diverse malignancies. Qualitative and
quantitative detection of ctDNA in these diseases provides
prognostic information that may ultimately be used to improve
risk stratification approaches. In order to move this finding into
the clinic, we are planning a larger prospective validation study
that will also assess the clinical utility of serial ctDNA samples
during treatment. We will investigate whether such data could
provide an early indication of chemoresponsiveness and serve as a
minimal residual disease marker. Finally, with refinement of our
assays and improved sample collection, we will further explore the
capacity of these two technologies to uncover important tumour
characteristics in the peripheral blood, which may provide key
information at diagnosis, and inform our understanding of the
clonal evolution of these sarcomas during treatment.
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